174 related articles for article (PubMed ID: 28148911)
1. High density lipoprotein (HDL) particles from end-stage renal disease patients are defective in promoting reverse cholesterol transport.
Anderson JL; Gautier T; Nijstad N; Tölle M; Schuchardt M; van der Giet M; Tietge UJ
Sci Rep; 2017 Feb; 7():41481. PubMed ID: 28148911
[TBL] [Abstract][Full Text] [Related]
2. P2Y13 receptor is critical for reverse cholesterol transport.
Fabre AC; Malaval C; Ben Addi A; Verdier C; Pons V; Serhan N; Lichtenstein L; Combes G; Huby T; Briand F; Collet X; Nijstad N; Tietge UJ; Robaye B; Perret B; Boeynaems JM; Martinez LO
Hepatology; 2010 Oct; 52(4):1477-83. PubMed ID: 20830789
[TBL] [Abstract][Full Text] [Related]
3. High-Density Lipoprotein Proteomic Composition, and not Efflux Capacity, Reflects Differential Modulation of Reverse Cholesterol Transport by Saturated and Monounsaturated Fat Diets.
O'Reilly M; Dillon E; Guo W; Finucane O; McMorrow A; Murphy A; Lyons C; Jones D; Ryan M; Gibney M; Gibney E; Brennan L; de la Llera Moya M; Reilly MP; Roche HM; McGillicuddy FC
Circulation; 2016 May; 133(19):1838-50. PubMed ID: 27081117
[TBL] [Abstract][Full Text] [Related]
4. [Role of HDL in Cholesterol Efflux and Reverse Cholesterol Transport].
Ayaori M
Rinsho Byori; 2016 Jan; 64(1):57-65. PubMed ID: 27192798
[TBL] [Abstract][Full Text] [Related]
5. Coffee consumption enhances high-density lipoprotein-mediated cholesterol efflux in macrophages.
Uto-Kondo H; Ayaori M; Ogura M; Nakaya K; Ito M; Suzuki A; Takiguchi S; Yakushiji E; Terao Y; Ozasa H; Hisada T; Sasaki M; Ohsuzu F; Ikewaki K
Circ Res; 2010 Mar; 106(4):779-87. PubMed ID: 20075335
[TBL] [Abstract][Full Text] [Related]
6. Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease.
Vaziri ND
J Ren Nutr; 2010 Sep; 20(5 Suppl):S35-43. PubMed ID: 20797569
[TBL] [Abstract][Full Text] [Related]
7. Oxidative stress and high-density lipoprotein function in Type I diabetes and end-stage renal disease.
Kalogerakis G; Baker AM; Christov S; Rowley KG; Dwyer K; Winterbourn C; Best JD; Jenkins AJ
Clin Sci (Lond); 2005 Jun; 108(6):497-506. PubMed ID: 15634192
[TBL] [Abstract][Full Text] [Related]
8. Scavenger receptor type BI potentiates reverse cholesterol transport system by removing cholesterol ester from HDL.
Kinoshita M; Fujita M; Usui S; Maeda Y; Kudo M; Hirota D; Suda T; Taki M; Okazaki M; Teramoto T
Atherosclerosis; 2004 Apr; 173(2):197-202. PubMed ID: 15064092
[TBL] [Abstract][Full Text] [Related]
9. Urokinase-type plasminogen activator (uPA) decreases hepatic SR-BI expression and impairs HDL-mediated reverse cholesterol transport.
Chulsky S; Paland N; Lazarovich A; Fuhrman B
Atherosclerosis; 2014 Mar; 233(1):11-8. PubMed ID: 24529115
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of stearoyl-coenzyme A desaturase 1 in macrophages promotes reverse cholesterol transport.
Nakaya K; Ayaori M; Uto-Kondo H; Sotherden GM; Nishida T; Katamoto H; Miura Y; Takiguchi S; Yakushiji E; Iizuka M; Ogura M; Sasaki M; Yogo M; Komatsu T; Adachi T; Maruyama C; Ikewaki K
Biochim Biophys Acta; 2013 Aug; 1831(8):1402-11. PubMed ID: 23747827
[TBL] [Abstract][Full Text] [Related]
11. Clinically used selective estrogen receptor modulators affect different steps of macrophage-specific reverse cholesterol transport.
Fernández-Suárez ME; Escolà-Gil JC; Pastor O; Dávalos A; Blanco-Vaca F; Lasunción MA; Martínez-Botas J; Gómez-Coronado D
Sci Rep; 2016 Sep; 6():32105. PubMed ID: 27601313
[TBL] [Abstract][Full Text] [Related]
12. Age-associated decrease of high-density lipoprotein-mediated reverse cholesterol transport activity.
Berrougui H; Khalil A
Rejuvenation Res; 2009 Apr; 12(2):117-26. PubMed ID: 19405812
[TBL] [Abstract][Full Text] [Related]
13. New insights into the regulation of HDL metabolism and reverse cholesterol transport.
Lewis GF; Rader DJ
Circ Res; 2005 Jun; 96(12):1221-32. PubMed ID: 15976321
[TBL] [Abstract][Full Text] [Related]
14. The impact of gender and serum estradiol levels on HDL-mediated reverse cholesterol transport.
Badeau RM; Metso J; Kovanen PT; Lee-Rueckert M; Tikkanen MJ; Jauhiainen M
Eur J Clin Invest; 2013 Apr; 43(4):317-23. PubMed ID: 23397902
[TBL] [Abstract][Full Text] [Related]
15. Dysfunctional high-density lipoproteins in children with chronic kidney disease.
Kaseda R; Jabs K; Hunley TE; Jones D; Bian A; Allen RM; Vickers KC; Yancey PG; Linton MF; Fazio S; Kon V
Metabolism; 2015 Feb; 64(2):263-73. PubMed ID: 25467845
[TBL] [Abstract][Full Text] [Related]
16. Dysfunctional high-density lipoprotein in patients on chronic hemodialysis.
Yamamoto S; Yancey PG; Ikizler TA; Jerome WG; Kaseda R; Cox B; Bian A; Shintani A; Fogo AB; Linton MF; Fazio S; Kon V
J Am Coll Cardiol; 2012 Dec; 60(23):2372-9. PubMed ID: 23141484
[TBL] [Abstract][Full Text] [Related]
17. Cholesterol efflux and reverse cholesterol transport.
Favari E; Chroni A; Tietge UJ; Zanotti I; Escolà-Gil JC; Bernini F
Handb Exp Pharmacol; 2015; 224():181-206. PubMed ID: 25522988
[TBL] [Abstract][Full Text] [Related]
18. Extended-Release Niacin/Laropiprant Improves Overall Efficacy of Postprandial Reverse Cholesterol Transport.
El Khoury P; Waldmann E; Huby T; Gall J; Couvert P; Lacorte JM; Chapman J; Frisdal E; Lesnik P; Parhofer KG; Le Goff W; Guerin M
Arterioscler Thromb Vasc Biol; 2016 Feb; 36(2):285-94. PubMed ID: 26681758
[TBL] [Abstract][Full Text] [Related]
19. Hepatic lipase- and endothelial lipase-deficiency in mice promotes macrophage-to-feces RCT and HDL antioxidant properties.
Escolà-Gil JC; Chen X; Julve J; Quesada H; Santos D; Metso J; Tous M; Jauhiainen M; Blanco-Vaca F
Biochim Biophys Acta; 2013 Apr; 1831(4):691-7. PubMed ID: 23328279
[TBL] [Abstract][Full Text] [Related]
20. SR-BI: A Multifunctional Receptor in Cholesterol Homeostasis and Atherosclerosis.
Linton MF; Tao H; Linton EF; Yancey PG
Trends Endocrinol Metab; 2017 Jun; 28(6):461-472. PubMed ID: 28259375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
